Holistic care in mild upper respiratory tract infections (MURTIs): an approach to individualized care management. [PDF]
Smith A +6 more
europepmc +1 more source
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane +33 more
wiley +1 more source
Role of Lipidomics in Respiratory Tract Infections: A Systematic Review of Emerging Evidence. [PDF]
Georgakopoulou VE, Dodos K, Pitiriga VC.
europepmc +1 more source
The TRIP database showed most Acute Respiratory Infections questions were already addressed by Cochrane reviews [PDF]
Brassey, Jon +4 more
core +1 more source
Viral and Atypical Pathogens Epidemiology of a Large Cohort of Patients with Acute Respiratory Tract Infections in Shaanxi Province, Northwest China [PDF]
Meng Li +5 more
openalex +1 more source
Relationships of Upper respiratory tract infections and holistic diets and lifestyles in Northeast China. [PDF]
Wang H +9 more
europepmc +1 more source
Objective We evaluated serious infection risk in offspring exposed to tumour necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011‐2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman +6 more
wiley +1 more source
Therapeutic efficacy of aerosolized moxifloxacin in respiratory tract infection in goats [PDF]
Ravi Shankar Kumar Mandal +8 more
openalex
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi +12 more
wiley +1 more source

